MIRM · Mirum Pharmaceuticals Inc
United States · RS rating 44 · As of 2026-11-03
| Price | 87.03 USD |
|---|---|
| 1-day change | +1.5% |
| RS rating (overall / 1M / 3M / 12M) | 44 / 76 / 34 / 68 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 34 / 29 / 21 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -12063.5% |
| Sales growth Q/Q | +12.0% |
| Distance from 52-week high | +32.3% |
| Market cap (USD) | $5.5B |